COMMISSION REGULATION (EU) No …/..
of XXX
amending Annex XIV to Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH)
(Text with EEA relevance)
THE EUROPEAN COMMISSION,
Having regard to the Treaty on the Functioning of the European Union,
Having regard to Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), establishing a European Chemicals Agency, amending Directive 1999/45/EC and repealing Council Regulation (EEC) No 793/93 and Commission Regulation (EC) No 1488/94 as well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC 1 , and in particular Articles 58 and 131 thereof,
Whereas:
(1)The substances 1,2-benzenedicarboxylic acid, dihexyl ester, branched and linear, and dihexyl phthalate and the substance group 1,2-benzenedicarboxylic acid, di-C6-10-alkyl esters; 1,2-benzenedicarboxylic acid, mixed decyl and hexyl and octyl diesters with ≥ 0,3% of dihexyl phthalate meet the criteria for classification as toxic for reproduction (category 1B) in accordance with Regulation (EC) No 1272/2008 of the European Parliament and of the Council 2 and therefore meet the criteria for inclusion in Annex XIV to Regulation (EC) No 1907/2006 set out in Article 57(c) of that Regulation.
(2)The substance trixylyl phosphate meets the criteria for classification as toxic for reproduction (category 1B) in accordance with Regulation (EC) No 1272/2008 and therefore meets the criteria for inclusion in Annex XIV to Regulation (EC) No 1907/2006 set out in Article 57(c) of that Regulation.
(3)The substances sodium perborate; perboric acid, sodium salt and sodium peroxometaborate meet the criteria for classification as toxic for reproduction (category 1B) in accordance with Regulation (EC) No 1272/2008 and therefore meet the criteria for inclusion in Annex XIV to Regulation (EC) No 1907/2006 set out in Article 57(c) of that Regulation.
(4)The substances 5-sec-butyl-2-(2,4-dimethylcyclohex-3-en-1-yl)-5-methyl-1,3-dioxane [1], 5-sec-butyl-2-(4,6-dimethylcyclohex-3-en-1-yl)-5-methyl-1,3-dioxane [2] (covering any of the individual stereoisomers of [1] and [2] or any combination thereof) (‘karanal group’) are very persistent and very bioaccumulative in accordance with the criteria set out in Annex XIII to Regulation (EC) No 1907/2006 and therefore meet the criteria for inclusion in Annex XIV to that Regulation set out in Article 57(e) of that Regulation.
(5)The substances 2-(2H-benzotriazol-2-yl)-4,6-ditertpentylphenol (UV-328); 2,4-di-tert-butyl-6-(5-chlorobenzotriazol-2-yl)phenol (UV-327); 2-(2H-benzotriazol-2-yl)-4-(tert-butyl)-6-(sec-butyl)phenol (UV-350) and 2-benzotriazol-2-yl-4,6-di-tert-butylphenol (UV-320) are persistent, bioaccumulative and toxic and/or very persistent and very bioaccumulative in accordance with the criteria set out in Annex XIII to Regulation (EC) No 1907/2006 and therefore meet the criteria for inclusion in Annex XIV to that Regulation set out in Article 57(d) and/or (e) of that Regulation.
(6)All the above-mentioned substances have been identified and included in the candidate list in accordance with Article 59 of Regulation (EC) No 1907/2006. They have furthermore been prioritised for inclusion in Annex XIV to Regulation (EC) No 1907/2006 by the European Chemicals Agency (‘the Agency’) in its recommendations of 10 November 2016 3 and 5 February 2018 4 , in accordance with Article 58(3) and (4) of that Regulation. In addition, the Commission has received submissions from interested parties to calls for information on the possible economic, social, health and environmental impacts (costs and benefits) of the inclusion in Annex XIV to Regulation (EC) No 1907/2006 of the substances proposed by the Agency in its draft recommendations.
(7)The substance diazene-1,2-dicarboxamide (C,C'-azodi(formamide)) (ADCA) meets the criteria for classification as a respiratory sensitiser (category 1) in accordance with section 3.4 of Annex I to Regulation (EC) No 1272/2008. This substance has been identified in accordance with Article 57(f) of Regulation (EC) No 1907/2006 due to its respiratory sensitising properties, for which there is scientific evidence of probable serious effects to human health which give rise to an equivalent level of concern to those of other substances listed in points (a) to (e) of Article 57 of that Regulation. This substance was included in the candidate list in accordance with Article 59 and prioritised for inclusion in Annex XIV to that Regulation by the Agency's recommendation of 6 February 2014 5 , in accordance with Article 58(3) and (4) of that Regulation. In Commission Regulation (EU) 2017/999 6 it was decided to postpone the inclusion of this substance in Annex XIV to Regulation (EC) No 1907/2006 as the experience for handling authorisation applications covering broad ranges of uses was still limited at that time. In the light of the experience gained in processing applications for authorisation regarding substances with very diverse uses, the Commission considers it appropriate to now include this substance in Annex XIV to Regulation (EC) No 1907/2006.
(8)For each of the substances included in Annex XIV to Regulation (EC) No 1907/2006 by this Regulation a date from which the placing on the market and the use of the substance shall be prohibited unless an authorisation is granted should be set as required by Article 58(1)(c)(i) of Regulation (EC) No 1907/2006, taking into account the Agency’s capacity to handle applications for authorisation. For each of those substances there are no reasons why the date referred to in Article 58(1)(c)(ii) of Regulation (EC) No 1907/2006 should be set earlier than 18 months before the date referred to in Article 58(1)(c)(i) of that Regulation.
(9)Article 58(1)(e) in conjunction with Article 58(2) of Regulation (EC) No 1907/2006 provides for the possibility of exemptions of uses or categories of uses in cases where specific Union legislation imposes minimum requirements relating to the protection of human health or the environment ensuring proper control of the risks. In accordance with the information currently available it is not appropriate to set exemptions based on those provisions.
(10)As there is no information justifying the need for an exemption for product and process orientated research and development, it is not appropriate to consider any such exemption.
(11)As the available information on the uses of the proposed substances is limited, it is not appropriate to set review periods at this stage, pursuant to Article 58(1)(d) of Regulation (EC) No 1907/2006 .